Published in J Urol on June 01, 2006
Practice patterns and recurrence after partial cystectomy for bladder cancer. World J Urol (2009) 1.49
Bladder cancer in the elderly. Urol Oncol (2009) 1.26
Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther (2010) 0.91
Contemporary management of muscle-invasive bladder cancer. Int J Clin Oncol (2008) 0.87
Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy. Ther Adv Urol (2011) 0.87
Tissue engineering for the oncologic urinary bladder. Nat Rev Urol (2012) 0.85
Impact of treatment delay in patients with bladder cancer managed with partial cystectomy in Quebec: a population-based study. Can Urol Assoc J (2009) 0.82
Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer (2014) 0.81
Robotic partial cystectomy for lymphangioma of the urinary bladder in an adult woman. Can Urol Assoc J (2012) 0.80
Deceptive muscle invasive bladder cancer recurrence with benign biopsy foci after bladder sparing treatment. Medicine (Baltimore) (2015) 0.77
Bladder cancer: in search of the right operation for the right patient. J Urol (2006) 0.75
Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery? Urol Clin North Am (2015) 0.75
Where are we with bladder preservation for muscle-invasive bladder cancer in 2017? Indian J Urol (2017) 0.75
Robot-assisted partial cystectomy with intraoperative frozen section examination: Evolution and evaluation of a novel technique. Investig Clin Urol (2016) 0.75
Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know? Bladder Cancer (2015) 0.75
Cystoscopic-assisted partial cystectomy: description of technique and results. Res Rep Urol (2014) 0.75
Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience. Int Sch Res Notices (2014) 0.75
Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes. World J Urol (2017) 0.75
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol (2013) 4.72
Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol (2004) 4.51
Epidemiology and risk factors of urothelial bladder cancer. Eur Urol (2012) 4.45
Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst (2005) 4.01
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer (2009) 3.12
An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis (2012) 3.11
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res (2009) 3.07
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Focus on bladder cancer. Cancer Cell (2004) 2.59
Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res (2008) 2.37
Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol (2003) 2.30
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica (2008) 2.26
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet (2006) 2.22
P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol (2007) 2.21
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol (2005) 2.17
Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst (2002) 2.16
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology (2003) 2.13
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev (2009) 2.09
Positive surgical margins with renal cell carcinoma have a limited influence on long-term oncological outcomes of nephron sparing surgery. Urology (2009) 2.07
Contemporary management of locally invasive bladder cancer. Oncology (Williston Park) (2011) 2.06
Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res (2005) 1.98
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol (2004) 1.91
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer (2008) 1.88
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int (2011) 1.85
Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr (2006) 1.73
The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol (2008) 1.73
Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology (2006) 1.72
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int (2006) 1.70
Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer (2007) 1.69
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol (2009) 1.68
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol (2012) 1.65
Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology (2006) 1.63
Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther (2004) 1.61
Survival in cancer patients undergoing in-hospital cardiopulmonary resuscitation: a meta-analysis. Resuscitation (2006) 1.59
Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res (2004) 1.59
Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther (2010) 1.55
Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int (2011) 1.55
Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol (2008) 1.54
Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol (2010) 1.53
The predominance of benign histology in small testicular masses. Urol Oncol (2011) 1.52
Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res (2003) 1.49
Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol (2010) 1.49
Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer (2007) 1.49
Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol (2011) 1.49
Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol (2007) 1.49
Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol (2010) 1.48
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology (2005) 1.48
Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer (2005) 1.47
Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer (2006) 1.47
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer (2009) 1.46
Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. Urology (2010) 1.46
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer (2010) 1.46
Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol (2012) 1.42
Office cystoscopy and transrectal ultrasound-guided prostate biopsies pose minimal risk: prospective evaluation of 921 procedures. Urology (2009) 1.42
Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin. PLoS One (2012) 1.42
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol (2007) 1.42
Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer (2009) 1.41
Hyperbaric oxygen therapy for hemorrhagic radiation cystitis. Isr Med Assoc J (2013) 1.41
ZKSCAN3 is a master transcriptional repressor of autophagy. Mol Cell (2013) 1.40
Decreased amplitude of detrusor overactivity by repetitive swallowing. J Urol (2012) 1.40
Cardiac history and risk of post-cystectomy cardiac complications. Urology (2009) 1.39
Pathologic evaluation of radical cystectomy specimens: a cooperative group report. Cancer (2004) 1.39